Immunotherapy | Topics

 
Immune Checkpoint Inhibitors May Be Effective, Safe in Geriatric Cancer
November 24, 2021

Retrospective data suggest survival outcomes were positive and safety was reasonable for patients with cancer aged 80 years or older who received immune checkpoint inhibitors.

Trial-Ineligible Patients With Advanced Solid Tumors More Likely to Receive Immune Checkpoint Inhibitor Monotherapy
November 17, 2021

Patients with advanced cancers who were ineligible for trials were more likely to receive frontline immune checkpoint inhibitor monotherapy than patients with the same advanced cancers who were eligible for trials.

Clinical Decision-Making in NSCLC
October 25, 2021

Roy S. Herbst, MD, PhD, shares insight on approaching clinical decision-making for the length of immunotherapy treatment and drug holidays for patients with NSCLC.

Role of ctDNA in Monitoring Treatment Response in NSCLC
October 25, 2021

An expert in thoracic oncology provides an overview of ctDNA and discusses what ctDNA testing results can indicate about a patient’s likelihood of responding to immunotherapy in NSCLC.

Monitoring Response to Therapy in NSCLC
October 18, 2021

Roy S. Herbst, MD, PhD, reviews indicators of relapse or progression of disease when monitoring patients on therapy in NSCLC.

Treatment Options in Non–Small Cell Lung Cancer
October 18, 2021

Roy S. Herbst, MD, PhD, provides insight on selecting the optimal therapy for non–small-cell lung cancer and shares considerations for the use of combination chemotherapy and immunotherapy.

Jason Luke, MD, Discusses Advancement of Immunotherapy For Metastatic Disease at 2021 ESMO
September 22, 2021

CancerNetwork® sat down with Jason Luke, MD, at the 2021 European Society for Medical Oncology Congress to talk about the latest developments in the use of immunotherapy for metastatic disease.

PD-1 and PD-L1 Inhibitors Yield a Higher Risk of AEs in Combination With Chemotherapy vs Targeted Therapy or Immunotherapy
September 21, 2021

The toxicity profiles of PD-1 and PD-L1 inhibitors displayed unique characteristics when combines with other agents such as chemotherapy, targeted therapy, and immunotherapy.

VERSATILE-002 Trial to Enroll Previously Treated HPV+ HNSCC Per Protocol Amendment
June 03, 2021

A new treatment arm of a phase 2 trial examining PDS0101 plus pembrolizumab in patients with HPV-related head and neck cancers will be opened to patients with immune checkpoint inhibitor–pretreated disease.

Thomas Marron, MD, PhD, on the Safety, Feasibility, and Immunogenicity of Neoantigen Peptide Vaccine PGV-001
April 11, 2021

Marron discussed the primary objectives and early data from a phase 1 trial presented at the virtual AACR Annual Meeting regarding the neoantigen peptide vaccine, PGV-001.